Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,430.64
(
-0.94%
)
US TECH 100
28,443.60
(
-1.21%
)
Dow Jones
49,559.26
(
-1.01%
)
Brent Oil
106.59
(
2.31%
)
Bitcoin
79,228.78
(
-2.26%
)
News Focus
News Focus
Post# of 257573
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122986
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 138597

Tuesday, 03/13/2012 7:36:39 AM

Tuesday, March 13, 2012 7:36:39 AM

Post# of 257573

Does this mean PFE is out of Biosimilar on insulin now?

It would appear so. The main impediment to the PFE-Biocon insulin collaboration could have been the existence of Biocon’s broad FoB collaboration with MYL (#msg-72421544), which PFE may have perceived as a conflict of interest. Nevertheless, PFE is pushing ahead on its own with FoB’s for non-insulin drugs—e.g. #msg-72865371.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today